Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 87,928	$ 169,681
Marketable securities	203,509
Prepaid expenses and other current assets	2,452	1,677
Total current assets	293,889	171,358
Long-term assets
Property and equipment, net	186	12
Operating lease right-of-use assets	2,798	407
Intangible assets, net	6,805	8,749
Long-term marketable securities	27,211
Other long-term assets	83	165
Total assets	330,972	180,691
Current liabilities
Accounts payable	8,882	3,149
Accrued compensation	4,776	3,135
Accrued clinical trial site costs	1,826	3,393
Operating lease liabilities	526	273
Other current liabilities	2,737	1,555
Total current liabilities	18,747	11,505
Long-term liabilities
Contingent liability for Essentialis purchase price	14,791	11,549
Long-term debt, net	49,828
Long-term lease liabilities	2,472	130
Other Liabilities, Noncurrent	21
Total liabilities	85,859	23,184
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value, 100,000,000 shares authorized, 45,703,811 and 31,678,159 shares issued and outstanding at December 31, 2024 and 2023, respectively	46	32
Additional paid-in-capital	696,966	433,885
Accumulated other comprehensive gain	361
Accumulated deficit	(452,260)	(276,410)
Total stockholders' equity	245,113	157,507
Total liabilities and stockholders'equity	$ 330,972	$ 180,691